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Abstract
Background: Chemotherapy‐induced	 peripheral	 neuropathy	 (CIPN)	 is	 a	 significant	
and	difficult	to	manage	side	effect	of	neurotoxic	chemotherapies.	Several	risk	fac‐
tors	for	CIPN	have	been	identified	to	date,	but	inconsistencies	and	methodological	
limitations	exist	in	past	research.	Also,	a	limited	number	of	potential	risk	factors	has	
been investigated in the past.
Aim: The objective of this study was to assess the relative contribution of a wider 
range of risk factors in the development of CIPN.
Methods: This	analysis	used	the	6‐month	data	after	starting	chemotherapy	from	a	
larger	prospective	observational	study	on	CIPN	risk,	prevalence,	and	quality	of	life.	
Patients	were	assessed	at	recruitment	for	possible	CIPN	risk	factors,	including	prior	
history	 of	 neuropathies,	 current/past	 infectious	 diseases;	 neurotoxic	 medication	
history;	 personal	 and	 treatment	 characteristics;	 smoking	 history,	 alcohol	 use,	 and	
vegetable/fruit	intake.	Neuropathy	was	assessed	at	6‐months	after	starting	chemo‐
therapy	with	the	neuropathy	(motor/sensory)	items	of	the	NCI‐CTCAE	scale	and	the	
WHO	criterion	for	neuropathy.	Data	on	symptom	burden	were	also	collected.
Results: Data	were	available	from	255	patients	from	three	cancer	centers	 in	Hong	
Kong,	Singapore,	and	UK.	The	use	of	different	scales	did	not	always	identify	the	same	
predictor	variables.	Key	risk	factors	in	multivariate	regression	models	included	older	
age	(highest	OR	=	1.08,	p	<	0.01	with	the	WHO	scale),	chemotherapy	(platinum‐based	
chemotherapy	had	OR	=	0.20–0.27	in	developing	CIPN	compared	to	taxane‐based	
chemotherapy),	history	of	neuropathy	 (for	motor	CIPN	only,	OR	=	8.36,	p	<	0.01),	
symptom	burden	 (OR	=	1.06,	p	 <	0.05),	 number	of	 chemotherapy	 cycles	 received	
(OR	=	1.19–1.24,	p	<	0.01),	 and	alcohol	 intake	 (OR	=	0.32,	p	<	0.05).	 In	univariate	
analysis,	the	use	of	statins	was	implicated	with	CIPN	(p	=	0.03–0.04	with	different	
assessments)	and	diabetes	showed	a	trend	(p	=	0.09)	in	the	development	of	CIPN.
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1  | INTRODUC TION
Chemotherapy‐induced	peripheral	neuropathy	(CIPN)	is	a	common	
side	effect	of	taxane‐	and	platinum‐based	chemotherapy,	with	prev‐
alence	ranging	from	12%–96%	(Eckhoff,	Knoop,	Jensen,	&	Ewertz,	
2015;	Osmani	et	al.,	2012;	Seretny	et	al.,	2014).	The	impact	of	CIPN	
on	patients’	quality	of	life	can	be	significant	(Ezendam	et	al.,	2014;	
Mols,	Beijers,	Vreugdenhil,	&	Poll‐Franse,	2014;	Seretny	et	al.,	2014).	
CIPN	may	be	challenging	for	clinicians	to	diagnose,	assess	and	man‐
age,	especially	in	patients	with	co‐existing	or	preexisting	conditions	
or	disorders	that	involve	the	peripheral	nervous	system	(Hausheer,	
Schilsky,	Bain,	Berghorn,	&	Lieberman,	2006).	A	general	predisposi‐
tion for developing CIPN is observed in nerves previously damaged 
by	 diabetes	 mellitus,	 alcohol,	 or	 inherited	 neuropathy	 (Quasthoff	
&	 Hartung,	 2002).	 Thyroid	 dysfunction,	 metabolic	 and	 infectious	
diseases	(i.e.,	hepatitis	B	or	C,	poliomyelitis,	HIV),	vitamin	deficien‐
cies	(i.e.,	B12,	B1,	B6),	and	monoclonal	gammopathy	have	also	been	
implicated	in	the	pathogenesis	of	CIPN	(Armstrong,	Almadrones,	&	
Gilbert,	2005;	Kaley	&	DeAngelis,	2009).	Many	medications	that	are	
commonly	used	in	cancer	patients,	such	as	metronidazole,	misoni‐
dazole,	sulfasalazine,	or	phenytoin,	are	all	documented	to	be	asso‐
ciated	with	 some	degree	of	peripheral	neurotoxicity	 (Hausheer	et	
al.,	2006).
Research around risk factors for CIPN has increased over re‐
cent	years,	although	at	times	findings	are	inconsistent	or	a	limited	
pool	of	potential	 factors	 is	assessed.	 In	a	 large	study	 (n	=	3,106),	
worse	 neurotoxicity	 was	 observed	 in	 colorectal	 cancer	 patients,	
those	with	longer	duration	of	cancer,	on	current	therapy,	older	pa‐
tients,	and	 in	African	Americans	 (Lewis	et	al.,	2015).	Being	obese	
and	having	more	 insomnia	severity,	anxiety,	and	depression	were	
all	associated	with	CIPN	in	other	studies	(Bao	et	al.,	2016;	Simon,	
Danso,	Alberico,	Basch,	&	Bennett,	2017).	Older	age,	lower	income,	
higher	BMI,	 comorbidities,	being	born	prematurely,	higher	cumu‐
lative	 dose	 of	 chemotherapy,	 and	 poorer	 functional	 status	 were	
also	 predictive	 of	 CIPN	 (Miaskowski	 et	 al.,	 2017).	 Diabetes	 was	
also	shown	to	be	predictor	of	CIPN	(Ottaiano	et	al.,	2016)	although	
other	studies	have	found	no	such	link	(Pereira	et	al.,	2016;	Simon	et	
al.,	2017).	However,	many	of	the	potential	predictors	of	CIPN	have	
not	 been	 fully	 investigated	 to	date.	Hence,	 the	 aim	of	 this	 study	
was to assess the relative contribution of a wider range of risk fac‐
tors	in	the	development	of	CIPN,	providing	a	stronger	explanatory	
model,	 and	 further	 explore	 the	 potential	 link	 between	CIPN	 and	
other symptoms.
2  | MATERIAL S AND METHODS
2.1 | Design
This	 analysis	 used	 data	 from	 the	 6‐month	 CIPN	 assessment	 after	
starting chemotherapy from a larger prospective observational 
study	 on	 CIPN	 prevalence	 and	 quality	 of	 life	 (Molassiotis	 et	 al.,	
2019),	focusing	on	one	of	the	primary	objectives	of	the	study.
2.2 | Sample and settings
The	 sample	 included	 patients	 receiving	 platinum‐based	 chemo‐
therapy	 (primarily	 cisplatin)	 and	 taxane‐based	 chemotherapy	
(primarily	 docetaxel)	 for	 the	 treatment	 of	 breast,	 lung,	 ovarian,	
gastrointestinal,	head	&	neck	as	well	as	urinary	tract	cancers.	Data	
were collected from specialist oncology clinics in three countries/
regions	 (Hong	 Kong,	 Singapore,	 and	Manchester	 in	 the	 UK).	 The	
study	was	 approved	 by	 the	 ethics	 committees	 of	 the	Hong	 Kong	
Polytechnic	University,	Hong	Kong;	Central	Cluster	of	the	Hospital	
Authority,	Hong	Kong;	The	National	University	Hospital;	Singapore;	
The	 University	 of	 Manchester,	 Manchester,	 UK;	 and	 the	 Central	
Manchester	Research	and	Ethics	Committee.	All	participants	have	
provided written informed consent.
3  | PROCEDURES
Eligible patients were identified and approached at hospital out‐
patients clinics. Those who agreed to participate and provided in‐
formed signed consent completed all the baseline measurements 
including personal characteristics and presence of potential risk fac‐
tors as identified in the literature. Clinical data were obtained from 
the medical records as well as information on medication used and 
past medical history. Participants in the larger project underwent 
a neuropathy assessment repeated at each cycle of chemotherapy 
(up	 to	 six	 cycles),	 6	months,	 9	months,	 and	12	months	postchem‐
otherapy.	For	 the	current	analysis,	data	 from	 the	6‐month	assess‐
ment were used as it had the highest number of patients across all 
Conclusion: This study confirmed the CIPN risk related to certain variables and iden‐
tified new ones. This knowledge can assist with treatment decisions and patient 
education.
K E Y W O R D S
cancer,	chemotherapy‐induced	peripheral	neuropathy,	platinum	chemotherapy,	risk	factors,	
taxanes
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assessments and the highest incidence of CIPN. Ethical approval was 
obtained from each site before commencing the study.
4  | OUTCOME ME A SURES
4.1 | Risk assessment
Potential	risk	factors	identified	previously	in	the	literature	(Armstrong	
et	al.,	2005;	Hauseer	et	al.,	2006;	Kaley	&	DeAngelis,	2009;	Miaskowski	
et	al.,	2017;	Ottaiano	et	al.,	2016;	Quasthoff	&	Hartung,	2002)	were	
examined	for	their	impact	in	the	development	of	CIPN.	These	included:
•	 Diagnosis	with	 acquired	 or	 hereditary	 neuropathy	 such	 as	 dia‐
betes,	 renal	disease,	hypothyroidism,	connective	tissue	disease.	
Prior history of neuropathy or family history of neuropathy; vi‐
tamin	deficiencies	(Hershman	et	al.,	2016;	Ottaiano	et	al.,	2016;	
Seretny	et	al.,	2014).
•	 Diagnosis	 with	 current	 or	 previous	 infectious	 diseases	 (HIV;	
Poliomyelitis;	Hepatitis	B	or	C;	Armstrong	et	 al.,	2005;	Kaley	&	
DeAngelis,	2009;	Seretny	et	al.,	2014).
•	 Neurotoxic	 medication	 history	 (a	 list	 of	 51	 medications	 linked	
with	neurotoxicity,	such	as	cyclosporine,	vancomycin,	cimetidine,	
etc;	Hauseer	et	al.,	2006;	Kaley	&	DeAngelis,	2009;	Quasthoff	&	
Hartung,	2002).
• Personal and treatment characteristics:
o	 Age	(Lewis	et	al.,	2015;	Miaskowski	et	al.,	2017,	2018).
o	 Disease	site	(Quasthoff	&	Hartung,	2002;	Seretny	et	al.,	2014;	
Simon	et	al.,	2017).
o	 Chemotherapy	type	(taxanes;	platinum‐based	chemotherapy;	
combination	 of	 taxanes	 and	 platinum‐based	 chemotherapy),	
number	 of	 chemotherapy	 cycles,	 and	 cumulative	 dosage	 of	
each	 neurotoxic	 chemotherapy	 drug	 (Kaley	 &	 DeAngelis,	
2009;	Quasthoff	&	Hartung,	2002;	Simon	et	al.,	2017).
o	 Smoking	history	 (never	 smoked;	 current	 smoker;	 ex‐smoker;	
Kawakami	et	al.,	2012;	Seretny	et	al.,	2014).
o	 History	of	alcohol	intake	(Pereira	et	al.,	2016)	(drinks	per	day	
(number)	using	an	explanatory	diagram	on	quantity	(i.e.,	small	
glass	of	wine	(120	ml)	=	1	drink,	etc).
o	 Dietary	history	(servings	of	fruits	and	vegetables	per	day	with	
explanations,	i.e.,	1	serve	=	1	fruit)	(Greenlee	et	al.,	2016).
4.2 | Neurotoxicity assessment
1.	 The	National	Cancer	 Institute	–	Common	Terminology	Criteria	
for	 Adverse	 Events	 (NCI‐CTCAE)	 version	 4.03	 is	 a	 physician‐
rated grading system that includes criteria and definitions for 
quantifying	 and	 grading	 CIPN.	 This	 grading	 scale	 comprises	
two	 items,	with	a	sensory	and	a	motor	assessment	and	utilizes	
a	 5‐point	 scale	 ranging	 from	 grade	 1	 to	 grade	 5.
2.	 The	WHO	criterion	 is	also	a	physician‐rated	CIPN	 item,	and	 in‐
cludes	paresthesia,	reflex	decreases	and	extend	of	motor	loss	as	
parameters	(WHO,	1979).
These two assessments were completed using both a checklist of neu‐
ropathy‐related	indications	and	physical/neurological	examination	to	aid	
in	the	diagnosis.	Also,	a	new	composite	variable	 (combined	scale,	sup‐
ported	by	the	combined	scale's	Cronbach	alpha	of	0.74,	 intraclass	cor‐
relation	of	0.74	and	item‐to‐item	correlations	of	0.41–0.61,	p	<	0.01)	was	
also	created	with	a	combination	of	the	above	three	items,	in	order	to	have	
maximum	variation	in	the	data,	as	the	two	scales	were	identifying	varying	
prevalence	of	CIPN	at	different	patients	(the	highest	prevalence	rate	with	
the	WHO	criterion	item).	This	combined	outcome	variable	was	flagged	as	
having CIPN when at least one of the three items used in the assessment 
of	CIPN	indicated	so,	and	it	was	used	in	the	risk	factor	analysis.
4.3 | Symptom burden
This	variable	responds	to	a	secondary	objective	of	the	study	to	explore	any	
links between CIPN and other symptoms. In order to estimate symptom bur‐
den,	we	used	data	from	the	single‐item	symptom	measures	(items	8,	9,	11–25	
of	the	European	Organization	for	Research	and	Treatment	(EORTC)	QLQ‐
C30.	It	incorporates	nine	multi‐item	scales	to	assess	quality	of	life:	five	func‐
tional	scales	(physical,	role,	cognitive,	emotional,	and	social);	three	symptom	
scales	(fatigue,	pain,	and	nausea	and	vomiting);	and	a	global	health	and	qual‐
ity‐of‐life	scale	(Aaronson	et	al.,	1993).	In	order	to	estimate	symptom	burden,	
we	used	data	from	the	single‐item	symptom	measures	(items	8,9,	11–25	of	the	
scale,	including	pain,	tiredness,	appetite	loss,	breathlessness,	nausea,	vomiting,	
constipation,	diarrhea,	cognitive	impairment,	psychological	symptoms)	after	
transforming	them	to	0–100	scores,	thus	creating	a	new	predictor	variable	of	
“symptom	burden”.	This	scale	has	been	validated	in	China	(Wan	et	al.,	2008)	
and	Singapore	(Tan	et	al.,	2014).	Its	Cronbach's	alpha	in	our	sample	was	0.90.
5  | DATA ANALYSIS
Descriptive	 statistics	 were	 used	 to	 summarize	 the	 data.	 Chi‐square	
analysis assessed differences in categorical variables while Student's t 
tests	were	used	for	comparing	continuous	variables.	Logistic	regression	
models were used for the main risk factor analysis. The relevant covari‐
ates for initial model inclusion were identified using a multivariate analy‐
sis,	with	rules	(p‐values	<	0.20)	for	retaining	variables	in	the	model.	This	
was	followed	by	the	final	model	which	only	included	significant	(defined	
above)	variables.	This	is	a	recommended	approach	for	removing	unim‐
portant covariates so that a more manageable set of variables can be 
used	with	more	complex	multivariate	statistical	techniques	(Lee,	2014).	
A	multilevel	 logistic	 regression	analyses	 took	place	 taking	account	of	
center	effect	and	time	since	last	cycle	of	chemotherapy,	to	develop	the	
predictive	model	for	CIPN.	Data	were	analyzed	using	SPSS	v.21.
6  | RESULTS
6.1 | Sample characteristics
Data	 from	 255	 participants	 were	 available	 for	 analysis	 at	 the	 6‐
month	 assessment	 of	 CIPN	 (chosen	 as	 this	 point	 had	 the	 highest	
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TA B L E  1  Chemotherapy‐induced	peripheral	neuropathy	and	its	risk	factors	in	categorical	variables	(n	=	255)
Variable Frequency
Chemotherapy‐induced peripheral neuropathy (CIPN) frequency and percentage in each scale
CTCAE‐motor CTCAE‐sensory WHO item
Combined CIPN 
scales
Overall 255	(100%) 36	(14.1%) 33	(12.9%) 45	(17.6%) 68	(26.7%)
Race
Chinese 210	(82.4%) 30	(14.3%) 26	(12.4%) 34	(16.2%) 55	(26.2%)
Non‐Chinese	Asians 23	(9.0%) 3	(13.0%) 4	(17.4%) 9	(39.1%) 9	(39.1%)
Caucasian 22	(8.6%) 3	(13.6%) 3	(13.6%) 2	(9.1%) 4	(18.2%)
p‐value  0.98 0.79 0.01 0.26
Chemotherapy group
Taxanes 123	(48.2%) 25	(20.3%) 24	(19.5%) 30	(24.4%) 46	(37.4%)
Platinum 64	(25.1%) 4	(6.3%) 3	(4.7%) 6	(9.4%) 7	(10.9%)
Combined 68	(26.7%) 7	(10.3%) 6	(8.8%) 9	(13.2%) 15	(22.1%)
p‐value  0.02 0.008 0.02 <0.001
Treatment intent
Radical	(adjuvant) 157	(61.6%) 24	(15.3%) 19	(12.1%) 22	(14.0%) 39	(24.8%)
Radical	(neoadjuvant) 43	(16.9%) 6	(14.0%) 7	(16.3%) 10	(23.3%) 14	(32.6%)
Radical	(concurrent) 14	(5.5%) 1	(7.1%) 1	(7.1%) 0	(0.0%) 1	(7.1%)
Palliative 41	(16.1%) 5	(12.2%) 6	(14.6%) 13	(31.7%) 14	(34.1%)
p‐value  0.83 0.79 0.01 0.18
Chemotherapy protocol
Paclitaxel 27	(10.6%) 14	(51.9%) 15	(55.6%) 14	(51.9%) 15	(55.6%)
Docetaxel 96	(37.6%) 16	(16.7%) 31	(32.3%) 16	(16.7%) 31	(32.3%)
Cisplatin 41	(16.1%) 2	(4.9%) 3	(7.3%) 2	(4.9%) 3	(7.3%)
Oxaliplatin 20	(7.8%) 4	(20.0%) 4	(20.0%) 4	(20.0%) 4	(20.0%)
Carboplatin and 
docetaxel
28	(11.0%) 2	(7.1%) 3	(10.7%) 2	(7.1%) 3	(10.7%)
Carboplatin and 
paclitaxel
34	(13.3%) 7	(20.6%) 12	(35.3%) 7	(20.6%) 12	(35.3%)
p‐value  0.13 0.03 <0.001 <0.001
Diagnosis
Ovarian 25	(9.8%) 4	(16.0%) 4	(16.0%) 3	(12.0%) 7	(28.0%)
Lung 28	(11.0%) 1	(3.6%) 1	(3.6%) 1	(3.6%) 1	(3.6%)
Head	and	neck 17	(6.7%) 1	(5.9%) 1	(5.9%) 1	(5.9%) 2	(11.8%)
Breast 146	(57.3%) 25	(17.1%) 23	(15.8%) 32	(21.9%) 49	(33.6%)
Colorectal 15	(5.9%) 0	(0.0%) 0	(0.0%) 3	(20.0%) 0	(0.0%)
Others 24	(9.4%) 5	(20.8%) 4	(16.7%) 5	(20.8%) 5	(20.8%)
p‐value  0.15 0.25 0.15 0.02
Stage
I 41	(16.1%) 6	(14.6%) 5	(12.2%) 3	(7.3%) 9	(22.0%)
II 79	(31.0%) 14	(17.7%) 10	(12.7%) 17	(21.5%) 24	(30.4%)
III 84	(32.9%) 8	(9.5%) 9	(10.7%) 11	(13.1%) 18	(21.4%)
IV 51	(20.0%) 8	(15.7%) 9	(17.6%) 14	(27.5%) 17	(33.3%)
p‐value  0.49 0.71 0.04 0.34
Metronidazole 12	(4.7%) 3	(25.0%) 2	(16.7%) 3	(25.0%) 5	(41.7%)
p‐value  0.23 0.48 0.45 0.23
(Continues)
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CIPN	rate	and	highest	number	of	participants).	The	larger	study	had	
343	patients	at	baseline	and	2,399	observations	 in	 total,	although	
numbers decreased over time due to patients discontinuing chem‐
otherapy,	patient	death,	or	 relocation	of	patients.	There	were	162	
participants	 from	Hong	Kong	 (63.5%),	 78	 from	Singapore	 (30.6%),	
and	15	from	the	UK	(5.9%).	The	majority	were	breast	cancer	patients	
followed	by	lung	cancer	and	gynecological	cancer	patients,	receiving	
adjuvant	chemotherapy,	and	at	stage	II	or	III	of	their	cancer.	Sample	
characteristics	are	shown	in	Tables	1	and	2.	Analysis	with	individual	
chemotherapy	 types	 (i.e.,	 docetaxel	 or	 cisplatin)	was	done	 initially	
separately,	 and	 as	 common	 risk	 factor	 patterns	 were	 observed	
across	protocols,	the	whole	data	was	subsequently	analyzed	and	re‐
ported together.
Non‐Chinese	Asians	 (primarily	 of	Malay	 and	 Indian	origin)	 had	
higher	 risk	of	 developing	neuropathy	 than	Chinese	or	Caucasians,	
only	when	the	WHO	scale	was	used	(p	=	0.01).	Also,	patients	receiv‐
ing	platinum‐based	chemotherapy	had	lower	risk	of	developing	CIPN	
than	 those	 receiving	 taxane‐based	 chemotherapy	 (across	 all	 CIPN	
scales	used).	A	particularly	high	 incidence	of	developing	CIPN	was	
observed	in	patients	receiving	paclitaxel	compared	to	all	other	che‐
motherapy	protocols.	For	many	medications	 in	our	 list,	there	were	
not	enough	incidence	of	use	(i.e.,	minimum	of	5)	to	allow	for	further	
analysis.	Metronidazole	use	had	no	statistically	significant	difference	
(although	CIPN	incidence	was	high	in	this	group	of	patients).	Use	of	
statins was implicated in the development of sensory neuropathy 
and it was also statistically significant variable in the combined CIPN 
category	(p	=	0.04)	and	sensory	neuropathy	item	(p	=	0.03).	Diabetes	
showed	a	trend	(p	=	0.09)	with	sensory	CIPN	only.	History	of	neu‐
ropathy	was	predictive	of	CIPN	when	the	CTCAE	scale	was	used	and	
showed	trends	when	the	WHO	scale	was	used.	Hepatitis	was	not	a	
statistically	significant	risk	factor,	although	CIPN	incidence	was	high	
in this group of patients. Detailed data are presented in Table 1.
Table 2 shows statistically significant predictors in contin‐
uous	 variables.	 Consistently	 (older)	 age	 and	 number	 of	 chemo‐
therapy	 cycles	 received	 were	 significant	 risk	 factors.	 Alcohol	
intake was significant only when the combined scale was used. 
Symptom	burden	 (mean	of	 all	 symptoms	 from	 the	EORTC	 scale)	
was	also	 linked	with	CIPN	 in	 this	univariate	analysis,	alongside	a	
number of symptoms in at least the combined CIPN scale. These 
included	 pain	 interfering	with	 daily	 activities	 (p	 =	 0.02),	 trouble	
sleeping	(p	=	0.04),	being	tired	(p	=	0.01),	appetite	loss	(p	=	0.04),	
constipation	 (p	 =	0.001),	worrying	 (p	 =	0.054),	 and	difficulty	 re‐
membering	(p	=	0.01).	Fruit	and	vegetable	intake	were	not	linked	
with	 CIPN.	 A	 stepwise	 logistic	 regression	 just	 for	 the	 individual	
symptoms showed that two symptoms were linked with the higher 
risk	of	CIPN,	namely	difficulty	remembering	(OR	=	1.61,	p	<	0.05;	
95%	CI	=	1.10–2.34)	and	constipation	 (OR	=	2.06,	p	<	0.01;	95%	
CI	=	1.29–3.29).
The	final	multivariate	logistic	regression	model	(Table	3)	of	all	uni‐
variate predictors with p‐value	<	0.20	observed	in	the	previous	anal‐
yses	 showed	 that	 patients	 receiving	 platinum‐based	 chemotherapy	
had	 lower	 risk	 of	 CIPN	 compared	 to	 those	 receiving	 taxane‐based	
Variable Frequency
Chemotherapy‐induced peripheral neuropathy (CIPN) frequency and percentage in each scale
CTCAE‐motor CTCAE‐sensory WHO item
Combined CIPN 
scales
Statins 37	(14.5%) 7	(18.9%) 9	(24.3%) 9	(24.3%) 15	(40.5%)
p‐value  0.25 0.03 0.25 0.04
Gender
Male 49	(19.2%) 4	(8.2%) 3	(6.1%) 8	(16.3%) 9	(18.4%)
Female 206	(80.8%) 32	(15.5%) 30	(14.6%) 37	(18.0%) 59	(28.6%)
p‐value  0.18 0.11 0.79 0.14
Smoking history
Never 199	(78.0%) 29	(14.6%) 27	(13.6%) 36	(18.1%) 57	(28.6%)
Current 7	(2.7%) 1	(14.3%) 1	(14.3%) 3	(42.9%) 3	(42.9%)
Ex‐smoker 49	(19.2%) 6	(12.2%) 5	(10.2%) 6	(12.2%) 8	(16.3%)
p‐value  0.92 0.82 0.13 0.13
Diabetes 37	(14.5%) 5	(13.5%) 8	(21.6%) 7	(18.9%) 12	(32.4%)
p‐value  0.91 0.09 0.83 0.39
Hypothyroidism 6	(2.4%) 0	(0.0%) 0	(0.0%) 1	(16.7%) 1	(16.7%)
p‐value  0.40 0.43 0.71 0.58
History	of	neuropathy 13	(5.1%) 6	(46.2%) 4	(30.8%) 0	(0.0%) 6	(46.2%)
p‐value  0.001 0.049 0.09 0.10
Hepatitis	B	or	C 13	(5.1%) 1	(7.7%) 3	(23.1%) 4	(30.8%) 5	(38.5%)
p‐value  0.50 0.26 0.20 0.32
TA B L E  1   (Continued)
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chemotherapy; those with history of neuropathy had higher risk for 
(motor)	CIPN,	 as	well	 as	 older	 patients.	 Symptom	burden	had	 some	
contribution	to	(primarily	to	sensory)	CIPN.	Number	of	chemotherapy	
cycles received was also a strong predictor of CIPN. One unit of alcohol 
use	decreased	the	risk	of	CIPN	by	68%	(only	in	the	combined	scale).
7  | DISCUSSION
This study assessed CIPN clinical risk factors using a prospective 
design and a wide range of potential predictors. Overall CIPN in‐
cidence was lower in this study than that reported in the litera‐
ture,	and	this	has	to	do	probably	with	the	scales	used;	past	studies	
have	used	quality	of	life	scales	to	estimate	CIPN,	which	often	in‐
clude a range of general/broader items to indicate neuropathy. 
Also,	 clinician‐based	 assessments,	 such	 as	 the	NCI‐CTCAE	 tend	
to	underestimate	CIPN	 incidence	 (Dorsey	et	 al.,	 2019).	We	have	
explained	these	reasons	in	more	detail	 in	the	parent	larger	study	
(Molassiotis	et	al.,	2019).	However,	 in	a	systematic	review	it	was	
shown	that	CIPN	incidence	at	6	months	was	30%	(Seretny	et	al.,	
2014)	and	our	incidence	in	the	combined	tools	was	26%.	Key	risk	
factors	identified	include	older	age,	history	of	neuropathy,	symp‐
tom	burden,	alcohol	intake	(cautiously	accepted	as	a	risk	factor	in	
this study due to the small number of events needing further clari‐
fication	 in	the	future)	and	number	of	chemotherapy	cycles	used.	
Patients	 receiving	 platinum‐based	 chemotherapy	 had	 17%–27%	
less	chance	of	developing	CIPN	compared	to	those	receiving	tax‐
ane‐based	chemotheraopy.	Risk	factors	were	not	always	consist‐
ent across the scales used. This may reflect sensitivity or reliability 
issues	with	 the	various	 scales	measuring	CIPN.	As	 the	measure‐
ment	tool(s)	used	in	future	risk	factor	research	will	be	related	with	
the	identification	of	specific	risk	factors,	it	is	important	to	use	the	
most	reliable	and	valid	CIPN	scale	(Cavaletti	et	al.,	2013;	Dorsey	et	
al.,	2019)	or	a	combination	of	scales	to	maximize	the	“pick	up”	rates	
of	 these	 tools	 that	 will	 include	 both	 patient‐reported	 outcomes	
and	objective	CIPN	indicators,	such	as	with	the	Total	Neuropathy	
Score	clinical	version	(TNSc)	(McCrary	et	al.,	2017).
Older	age	somewhat	contributed	to	CIPN	(6%	more	chances),	
supporting	 findings	 from	 past	 research	 (Bandos	 et	 al.,	 2018;	
Hershman	et	al.,	2016;	Miaskowski	et	al.,	2017).	History	of	neu‐
ropathy was a potential risk factor for motor neuropathy and its 
ORs	were	high	in	the	other	CIPN	scales	(but	did	not	reach	statis‐
tical	 significance).	History	of	neuropathy	was	mainly	 linked	with	
motor	 CIPN,	with	 patients	 having	 such	 history	 being	more	 than	
eight times at a higher risk for developing motor CIPN. The limited 
research of the past does not differentiate the role of this variable 
in	the	type	of	neuropathy,	hence	this	is	a	novel	finding.	Statin	use	
as	a	risk	factor	for	CIPN	is	also	another	novel	finding	of	this	study,	
although this finding from univariate analysis was not sustained in 
the	final	model,	likely	because	of	the	small	number	of	patients	re‐
ceiving	statins	in	this	sample.	This	finding	supports	an	earlier	case‐
control	 study	on	patients	 receiving	 statins,	 although	 the	 sample	
in	 the	 latter	 study	was	not	 focusing	on	cancer	patients	 (Gaist	et	
al.,	2002).	However,	more	recent	work	from	a	case‐control	study	
showed that ever use of statins was not associated with a higher 
risk	of	polyneuropathy	(Svendsen	et	al.,	2017).	This	finding	needs	
further	elaboration	in	the	future,	although	if	a	risk	exists,	it	is	prob‐
ably	minimal.	Metronidazole	use	as	a	potential	risk	factor	should	
also	be	investigated	in	the	future,	as	the	incidence	of	CIPN	in	this	
subgroup	was	high	(up	to	41.7%)	and	literature	suggests	sensory	
and	autonomic	neuropathy	as	a	result	of	such	use	(Hobson‐Webb,	
Roach,	 &	 Donofrio,	 2006),	 although	 the	 small	 number	 of	 such	
cases may have contributed to the nonsignificant results shown. 
Such	 future	work	 should	 clearly	 delineate	 duration	 of	 use,	 dose	
and	timing	of	use,	which	were	not	collected	in	our	study	and	hence	
pose limitations in interpreting this result.
Symptom burden is a new variable implicated in the development 
of CIPN. Whether this finding is attributed to collinearity with CIPN 
or	symptom	burden	influencing	the	development	(and/or	severity)	of	
CIPN	is	not	yet	clear.	Two	particular	symptoms	(out	of	18	assessed)	
had	the	strongest	relationship	with	CIPN,	including	constipation	and	
difficulty remembering. It may be that neuronal damage related to 
CIPN leads to constipation or cognitive deficits in patients. The link 
between autonomic neuropathy and constipation may be the re‐
sult of neurogenic bowel/disautonomia or constipation may be one 
of the indications of constituent autonomic neuropathy. CIPN and 
cognitive changes such as difficulty remembering/”chemofog” may 
be	 link	as	a	 result	of	neuroinflammation	postchemotherapy,	which	
has	been	discussed	as	a	potential	mechanism	for	behavioral	toxici‐
ties	(Vichaya	et	al.,	2015).	It	will	be	interesting	to	explore	these	as‐
sumptions	in	the	future	more	concretely	and	have	a	more	in‐depth	
understanding of the link between symptoms/symptom burden and 
CIPN. This finding is further supported by recent research showing 
that patients with CIPN had significantly poorer functional status 
(Miaskowski	et	al.,	2017).
The	role	of	(chronic)	alcohol	use	in	the	development	of	CIPN	is	
less	clear,	as	contradictory	findings	have	been	presented	in	the	lit‐
erature,	probably	due	to	the	inherent	problems	in	measuring	alcohol	
use accurately. Our findings suggest that no alcohol use had some 
protective	effect	in	CIPN,	but	this	was	not	consistent	across	all	the	
scales	used.	Also,	our	sample	had	very	few	heavy	drinkers	and	this	
may	have	impacted	on	the	results.	Alcohol	use	(as	well	as	diabetes)	
may be associated with the development of neuropathy before the 
chemotherapy,	and	we	have	seen	that	preexisting	neuropathy	was	a	
key CIPN risk factor.
The number of chemotherapy cycles received was a strong pre‐
dictor both in univariate and multivariate analyses. This is not linked 
with	cumulative	dose	(as	the	latter	was	not	shown	to	be	predictive	
of	CIPN	in	our	study).	Hence,	this	finding	may	imply	that	“time”	after	
starting chemotherapy may be strongly linked with the development 
of	CIPN,	suggesting	that	CIPN	is	time‐dependent	rather	than	dose‐
dependent,	 although	 the	 link	 between	 cumulative	 dose	 and	CIPN	
has	been	reported	in	past	literature	but	not	consistently	(Seretny	et	
al.,	2014).
Two parameters in the final predictive model need some more 
consideration	in	the	development	of	CIPN.	Firstly,	the	role	of	hepa‐
titis	(possibly	as	a	result	of	taking	neurotoxic	antiviral	agents	in	the	
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past or even as a result of disturbance in the pharmacokinetics of the 
chemotherapy	drugs,	i.e.,	decreased	liver	function	and/or	increased	
drug	 exposition).	 Secondly,	 current	 smoking	with	 perhaps	 its	 con‐
nection	with	pain	pathways.	Both	of	them	had	very	high	odds	ratios	
(3.93	and	1.18–2.54,	respectively)	but	both	these	ORs	were	not	sta‐
tistically	significant,	highly	likely	as	a	result	of	the	small	number	of	
patients	reporting	these	two	variables	(n	=	13	and	7,	respectively).	
Future	research	should	provide	more	insight	about	the	potential	risk	
for CIPN for hepatitis and smoking status.
Some	variables	in	the	study	had	small	frequency	counts,	and	this	
may	affect	the	interpretation	and	generalizability	of	the	results	and	
should be perceived as preliminary only. Identification of risk factors 
may assist the clinician to make chemotherapy treatment decisions 
accordingly	in	order	to	minimize	not	only	the	development	of	CIPN	
but	also	the	morbidity	and	health	care	utilization	linked	with	higher	
incidence	of	CIPN	(while	clinical	effectiveness	is	not	compromized).	
However,	the	state	of	science	in	this	area	is	not	yet	optimal	for	such	
clinical	decisions,	and	more	research	in	elucidating	strong	CIPN‐re‐
lated	risk	factors	is	needed,	including	the	development	of	predictive	
models.	Other	consistent	risk	factors,	such	as	higher	BMI	and	obe‐
sity were not assessed in this study and these should be included in 
future models.
This	study	confirms	the	role	of	(older)	age;	number	of	chemo‐
therapy	cycles	 received,	and	 type	of	 chemotherapy	as	key	CIPN	
risk factors. The role of past neuropathic damage specifically 
linked	 with	 motor	 CIPN	 and	 (chronic)	 alcohol	 consumption	 are	
also important new variables to consider alongside the presence 
of symptom burden/specific symptoms that may form a symp‐
tom cluster around neuropathy. Risk factor knowledge can assist 
health professionals in educating patients in a more targeted way 
about	 this	 symptom	 experience	 and	 introduce	 more	 regular	 as‐
sessment	of	CIPN	particularly	 in	 those	at	higher	 risk,	 in	order	 to	
monitor its development and the impact it may have on patients’ 
quality	of	life.	Preventive	interventions	may	need	to	be	initiated	to	
those with high risk of CIPN.
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